Dulaglutide (Trulicity)
Overview
A long-acting GLP-1 receptor agonist consisting of a GLP-1 analog covalently linked to a modified human IgG4 Fc fragment via a peptide linker. This fusion protein design increases molecular size to reduce renal clearance and enables FcRn-mediated recycling, producing a half-life of approximately 5 days suitable for once-weekly dosing. Dulaglutide activates pancreatic GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress glucagon.
Key Research Findings
AWARD trial program demonstrated superior HbA1c reduction vs. multiple comparators. REWIND trial (2019) showed 12% reduction in MACE in type 2 diabetes patients, including those without established cardiovascular disease. FDA-approved for type 2 diabetes (2014) and cardiovascular risk reduction.
Subcutaneous injection (weekly)
FDA Approved
Interested in Dulaglutide (Trulicity)?
Find a verified provider experienced with Dulaglutide (Trulicity) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Dulaglutide (Trulicity) ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.